



**Areacor Therapeutics plc**  
("Areacor" or the "Group")

**ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY**

***Areacor expands its global partnerships through collaboration to develop an enhanced antibody formulation***

**Cambridge, UK, 17 August 2023:** Areacor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs.

Under the terms of this agreement, Areacor will use its proprietary formulation technology platform, Arestat™, to develop a novel, stable formulation of a liquid, high concentration antibody. The collaborator will fund the development work, generating new revenue for Areacor. This agreement adds to Areacor's growing portfolio of partnerships.

***Sarah Howell, Chief Executive Officer of Areacor, said: "This collaborator is a leader in the development of novel medicines. Areacor has a proven track record of leveraging its Arestat technology to help deliver these complex therapeutics. We work closely with our partners to develop more effective treatments where superior properties bring even greater benefit to patients and we look forward to working with the world-renowned R&D team."***

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

**-ENDS-**

**For more information, please contact:**

**Areacor Therapeutics plc**

Dr Sarah Howell, Chief Executive Officer

[www.areacor.com](http://www.areacor.com)

Tel: +44 (0) 1223 426060

Email: [info@areacor.com](mailto:info@areacor.com)

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@areacor.com](mailto:info@areacor.com)



Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [mo.noonan@arecor.com](mailto:mo.noonan@arecor.com)

**Panmure Gordon (UK) Limited** (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

**Consilium Strategic Communications**

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: [arecor@consilium-comms.com](mailto:arecor@consilium-comms.com)

## Notes to Editors

### About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, [www.arecor.com](http://www.arecor.com)